Evolus (EOLS) Return on Capital Employed (2018 - 2026)
Evolus (EOLS) posted Return on Capital Employed of 15.68% for Q1 2026, up 29.38% on a QoQ basis from 22.2% in Q4 2025, and up 871.0% year-over-year from 1.61% in Q1 2025.
Evolus (EOLS) Return on Capital Employed (2018 - 2026) Analysis & Trends
Evolus' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 15.68% for Q1 2026.
- Quarterly Return on Capital Employed rose 871.0% year-over-year to 15.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.68% (up 871.0% YoY) and the FY2025 annual result came in at 21.22%, up 206.0% from the prior year.
- Return on Capital Employed was 15.68% for Q1 2026 at Evolus, up from 22.2% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 15.68% in Q1 2026 and bottomed at 48.3% in Q3 2022.
- A 5-year average of 32.83% and a median of 28.68% in 2024 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 9946 bps in 2022, while the deepest fall reached 2220 bps in 2022.
- Evolus' Return on Capital Employed stood at 47.05% in 2022, then rose by 20 bps to 37.82% in 2023, then soared by 46 bps to 20.47% in 2024, then fell by 8 bps to 22.2% in 2025, then climbed by 29 bps to 15.68% in 2026.
- Business Quant data shows EOLS's Return on Capital Employed at 15.68% in Q1 2026, 22.2% in Q4 2025, and 24.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -15.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.68% |
| Dec 31, 2025 | -22.20% |
| Sep 30, 2025 | -24.94% |
| Jun 30, 2025 | -27.44% |
| Mar 31, 2025 | -24.39% |
| Dec 31, 2024 | -20.47% |
| Sep 30, 2024 | -23.84% |
| Jun 30, 2024 | -22.01% |
| Mar 31, 2024 | -28.68% |
| Dec 31, 2023 | -37.82% |
| Sep 30, 2023 | -42.72% |
| Jun 30, 2023 | -45.18% |
| Mar 31, 2023 | -48.21% |
| Dec 31, 2022 | -47.05% |
| Sep 30, 2022 | -48.30% |
| Jun 30, 2022 | -45.01% |
| Mar 31, 2022 | -34.22% |
| Dec 31, 2021 | -24.85% |
| Sep 30, 2021 | -86.02% |
| Jun 30, 2021 | -111.51% |